Dr. Nigel Rulewski is Vice President, Global Strategic Drug Development at Quintiles and head of Quintiles Global Biosimilars Unit. In this capacity, he works with companies around the world advising on drug development strategies with an active focus in the area of biosimilar development. His experience spans multiple therapeutic areas, particularly oncology, respiratory medicine and biosimilars, and he has led development planning activities for EPO, GCSF, peg-GCSF, Remicade, Enbrel, Rituximab and Herceptin biosimilars.
Prior to joining Quintiles in 2008, Dr. Rulewski held numerous senior management positions, including Vice President of drug development for Astra for 10 years. In this role, he managed a department that expanded to more than 200 employees and achieved approval of multiple NDA’s in the areas of pain control, respiratory, cardiovascular and AIDS indications. Dr. Rulewski has also worked in venture capital in New York, establishing funding for multiple early stage start-up companies predominantly focused on oncology. He has also served as Chief Medical Officer for two oncology-focused biotechnology companies, Procept and Arqule.
Dr. Rulewski earned his medical degree from St. Bartholomew’s Medical School, University of London. After completing his training in pediatrics and obstetrics and gynecology, he practiced in the UK, in both London and Guildford.